Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal.  All content is subject to the portal’s Community Content Guidelines.

 


Why Pre-IND Is the Best Time to Get Involved With Glafabra

Glafabra
Posted at Aug 16

Pre-IND is a specific moment, and it doesn't last.

Right now, before Glafabra's IND is filed, is when Japan licensing terms, partnership structures, and — for this crowdfunding round — investment interest can be shaped at the earliest, most favorable stage of the company's life. Once a U.S. cohort is enrolling, the terms of every conversation change.

This isn't urgency for its own sake. It's just ...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Why Patient Registries Matter for Rare Disease Research

Glafabra
Posted at Aug 15

Patient registries don't get much attention, but they're doing quiet, essential work.

Organizations like the Fabry International Network and the National Fabry Disease Foundation maintain the patient communities, education, and advocacy infrastructure that make trials like ours possible to design well — and make sure patients hear about opportunities like this one in the first place.

If you're par...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

One Month After Glafabra's FDA INTERACT Meeting

Glafabra
Posted at Aug 14

One month since Glafabra's FDA INTERACT meeting.

That July 16 conversation shapes the IND protocol we're building now: endpoint strategy, patient selection criteria, conditioning approach. None of that gets finalized overnight — it's weeks of translating regulatory feedback into a protocol document.

For those tracking the timeline: IND filing stays targeted for mid-2027. First patient enrolled tar...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Can Fabry Disease Occur With No Family History? — DECODE No. 12

Glafabra
Posted at Aug 13

Answer to the question last time on August 10: a father passes his only X chromosome to every daughter and his Y to every son — so every daughter inherits his Fabry variant, and no son does.)

Most Fabry cases run in families. But every so often, someone is diagnosed with zero family history at all — no parent, no sibling, nothing in the records.

What causes Fabry disease to show up with no family ...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Why Does Live-cel Use Hematopoietic Stem Cells?

Glafabra
Posted at Aug 12

Why build a gene therapy around a blood stem cell instead of a virus alone?

A hematopoietic stem cell (HSC) — the cell that gives rise to your entire blood and immune system — can be corrected once, outside the body, and then put back in. It engrafts permanently, and its corrected descendants keep making the missing enzyme for years.

That's the foundation Live-cel is built on: harvest, correct, re...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Meet Glafabra's CEO & Co-Founder, Chris Hopkins

Glafabra
Posted at Aug 11

Meet the person leading this: Chris Hopkins, CEO & Co-Founder.

Chris is a geneticist, biochemist, and entrepreneur who's spent his career at the intersection of science and company-building. He guided the acquisition of Knudra Transgenics by InVivo Biosystems, raised over $5M in venture capital and $7M in non-dilutive SBIR funding, licensed CRISPR technology in 2014 — shortly after it was inve...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

Why Do All Daughters of an Affected Father Inherit Fabry Disease? — DECODE No. 11

Glafabra
Posted at Aug 10

(Answer to the question last time on August 6: Fabry disease is X-linked — the GLA gene sits on the X chromosome, so the pattern plays out differently for men and women.)

Here's the quirk that surprises people. A father with Fabry disease passes the condition to every single one of his daughters — but to none of his sons.

Why does it break down exactly that way? Drop your guess in the comments bel...more

Categories: Advanced Therapeutics  |  Cell & Gene Therapy  |  Clinical Research  |  Drug Development  |  Fabry Disease  |  Rare Disease
Tags:

One Month Into Testing the Waters: What We've Learned

Glafabra
Posted at Aug 9

A month ago, this was a handful of posts and a hope that people would care about a disease most of them had never heard of. Since then: real questions on this portal, real conversations, and people who registered interest before we'd even finished explaining why.

That's not nothing. Rare disease work runs on people willing to pay attention before there's a finished product to point to.

Thank you f...more

Categories: Cell & Gene Therapy  |  Fabry Disease  |  Rare Disease
Tags: